secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001493152-23-027724
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q2 revenue up 31% to $5.8M, net loss widens to $9.8M; cash $4.5M
----------------------------------------------------------------------------

- Revenue $5.8M (+31% YoY); net loss $9.8M ($7.23/share) vs $0.9M loss in Q2 2022.
- Cash $4.5M, down from $17.2M at Dec 31, 2022; equity investment in Biofrontera AG $5.9M.
- Founder Hermann Luebbert named CEO, continues as Executive Chairman.
- Affirms FY 2023 revenue growth at least 25%; expects cash flow positive within ~1.5 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/0001493152-23-027724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223027724/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer